Royal Bank of Canada
KPTI icon

Royal Bank of Canada’s Karyopharm Therapeutics KPTI Stock Holding History

Royal Bank of Canada’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$336K Buy
60,399
+2,399
+4% +$18.3K ﹤0.01% 4401
2025
Q4 		$427K Buy
58,000
+51,266
+761% +$314K ﹤0.01% 4284
2025
Q3 		$44K Sell
6,734
-695
-9% -$3.74K ﹤0.01% 5880
2025
Q2 		$32K Buy
7,429
+5,970
+409% +$29.3K ﹤0.01% 6106
2025
Q1 		$5K Buy
1,459
+1,026
+237% +$8.76K ﹤0.01% 6356
2024
Q4 		$4K Sell
433
-97
-18% -$1.17K ﹤0.01% 6585
2024
Q3 		$6K Sell
530
-3,227
-86% -$40.1K ﹤0.01% 6462
2024
Q2 		$48K Sell
3,757
-5,377
-59% -$89K ﹤0.01% 5676
2024
Q1 		$207K Buy
9,134
+4,046
+80% +$70.9K ﹤0.01% 4660
2023
Q4 		$66K Sell
5,088
-64
-1% -$862 ﹤0.01% 5858
2023
Q3 		$104K Sell
5,152
-1
-0% -$22 ﹤0.01% 5361
2023
Q2 		$139K Buy
5,153
+970
+23% +$41.8K ﹤0.01% 5069
2023
Q1 		$244K Sell
4,183
-99
-2% -$4.89K ﹤0.01% 4449
2022
Q4 		$218K Buy
4,282
+3,537
+475% +$245K ﹤0.01% 4802
2022
Q3 		$61K Sell
745
-143
-16% -$10.7K ﹤0.01% 5630
2022
Q2 		$59K Sell
888
-216
-20% -$19.8K ﹤0.01% 5638
2022
Q1 		$123K Sell
1,104
-968
-47% -$121K ﹤0.01% 5493
2021
Q4 		$200K Buy
2,072
+293
+16% +$29.2K ﹤0.01% 5330
2021
Q3 		$155K Buy
1,779
+332
+23% +$34.5K ﹤0.01% 5392
2021
Q2 		$224K Buy
1,447
+691
+91% +$100K ﹤0.01% 4979
2021
Q1 		$119K Buy
756
+359
+90% +$75.6K ﹤0.01% 5336
2020
Q4 		$92K Buy
397
+24
+6% +$5.56K ﹤0.01% 5382
2020
Q3 		$81K Buy
373
+4
+1% +$978 ﹤0.01% 5091
2020
Q2 		$104K Buy
369
+317
+610% +$93.8K ﹤0.01% 4830
2020
Q1 		$15K Sell
52
-56
-52% -$15.4K ﹤0.01% 5670
2019
Q4 		$32K Sell
108
-19
-15% -$4.12K ﹤0.01% 5658
2019
Q3 		$19K Buy
127
+40
+46% +$5.42K ﹤0.01% 5518
2019
Q2 		$8K Hold
87
– – ﹤0.01% 6107
2019
Q1 		$8K Buy
87
+67
+335% +$7.43K ﹤0.01% 6095
2018
Q4 		$3K Sell
20
-86
-81% -$14.5K ﹤0.01% 6336
2018
Q3 		$27K Buy
106
+96
+960% +$26.5K ﹤0.01% 5530
2018
Q2 		$3K Sell
10
-31
-76% -$7.67K ﹤0.01% 6163
2018
Q1 		$8K Sell
41
-7
-15% -$1.4K ﹤0.01% 5792
2017
Q4 		$7K Sell
48
-197
-80% -$31.6K ﹤0.01% 5979
2017
Q3 		$40K Buy
245
+188
+330% +$26.9K ﹤0.01% 5551
2017
Q2 		$8K Sell
57
-42
-42% -$6.22K ﹤0.01% 5885
2017
Q1 		$19K Sell
99
-20
-17% -$3.21K ﹤0.01% 5651
2016
Q4 		$17K Sell
119
-1
-0.8% -$135 ﹤0.01% 5859
2016
Q3 		$18K Buy
120
+27
+29% +$3.25K ﹤0.01% 5590
2016
Q2 		$9K Sell
93
-2,814
-97% -$366K ﹤0.01% 5782
2016
Q1 		$388K Buy
2,907
+142
+5% +$15.7K ﹤0.01% 3860
2015
Q4 		$549K Buy
2,765
+2,620
+1,807% +$567K ﹤0.01% 3683
2015
Q3 		$23K Buy
145
+85
+142% +$22.7K ﹤0.01% 5513
2015
Q2 		$24K Hold
60
– – ﹤0.01% 5612
2015
Q1 		$28K Buy
+60
New +$25.9K ﹤0.01% 5211
2014
Q4 		– Sell
-400
Closed -$210K – 6239
2014
Q3 		$210K Sell
400
-780
-66% -$440K ﹤0.01% 4155
2014
Q2 		$824K Buy
+1,180
New +$549K ﹤0.01% 2988

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Royal Bank of Canada's KPTI Position: Q1 2026 in Review

Royal Bank of Canada increased its Karyopharm Therapeutics (KPTI) stake by 4.1% in Q1 2026, buying an estimated $18.3K and bringing the position to 60,399 shares worth $336K. The position accounts for ﹤0.01% of the portfolio, ranked #4401.

Royal Bank of Canada first reported a position in KPTI in Q2 2014 and has held it in 47 quarters since. The position peaked at $824K in Q2 2014. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Royal Bank of Canada held 60,399 shares of Karyopharm Therapeutics worth $336K as of Q1 2026.
  • Royal Bank of Canada bought 2,399 Karyopharm Therapeutics shares in Q1 2026, an estimated $18.3K.
  • Karyopharm Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4401 holding.
  • Royal Bank of Canada first reported a position in Karyopharm Therapeutics in Q2 2014 and has held it in 47 quarters since.
  • Royal Bank of Canada's Karyopharm Therapeutics position peaked at $824K in Q2 2014.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.